Table 1 Baseline characteristics of patients
Variables | All (n = 42) |
|---|---|
Age, years, median (range) | 34 (21–58) |
Male sex, n (%) | 28 (66.7) |
ECOG PS score, n (%) | |
 0 | 41 (97.6) |
 1 | 1 (2.4) |
Ann Arbor stage at time of enrolment, n (%) | |
 II | 16 (38.1) |
 III | 7 (16.7) |
 IV | 19 (45.2) |
Extranodal involvement Extranodal involvement, n (%) | 23 (54.8) |
Histologic subtype, n (%) | |
 Nodular sclerosis cHL | 33 (78.6) |
 Mixed cellularity cHL | 7 (16.7) |
 Lymphocyte-rich cHL | 2 (4.8) |
B symptoms, n (%) | 14 (33.3) |
Prior treatment line, n (%) | |
 1 | 37 (88.1) |
 2 | 5 (11.9) |
First-line regimen, n (%) | |
 ABVD | 38 (90.5) |
 ABVD + BEACOPP | 2 (4.8) |
 ABVD + AVDP | 1 (2.4) |
 ABVD + CHOPE | 1 (2.4) |
Second-line regimen (n = 5), n (%) | |
 DICE | 3 (60.0) |
 CHOP | 1 (20.0) |
 GDPE | 1 (20.0) |
Prior radiotherapy, n (%) | 6 (14.3) |
Disease status, n (%) | |
 Refractory | 21 (50.0) |
 Relapsed within 1 year | 9 (21.4) |
 Relapsed after 1 year | 12 (28.6) |